<!doctype html>
<html>
<head>
<meta charset="UTF-8">
<meta name="apple-mobile-web-app-capable" content="yes">
<meta name="viewport" content="width=device-width initial-scale=1, user-scalable=no">
<meta name="apple-mobile-web-app-title" content="BRILINTA - Efficacy or Firstline">
<title>BRILINTA - Efficacy or Firstline</title>
<link rel="stylesheet" type="text/css" href="css/animate.min.css" />
<link rel="stylesheet" type="text/css" href="css/style.css" />
<style type="text/css">
    .contents > div:nth-child(2) {width:620px; position:relative; margin:120px auto 0px;}
    .small{font-size:26px; line-height:28px; color:white;}
    .small > li > div{display:table-cell; vertical-align:middle; margin:0 auto; text-align: center;}
    .small > li{display:table; height:112px; width:300px; background:url('img/buttons.png') no-repeat center; margin-bottom:45px; float:left;}
    .small > li:first-child{background-position-y:0px}
    .small > li:nth-child(2){background-position-y:-119px;}
    .small > li:last-child{background-position-y:-237px; width:620px;}

    table, th,  td{vertical-align: middle; border:1px solid white;}
    th{text-transform: uppercase; font-family: 'CodePro'; color:white; height:55px; background-color:#e45e22; width:150px; font-size:18px; line-height:22px;}
    th:first-child{text-align: left; width:597px; text-indent: 10px}
    td{font-size:17px; line-height:20px; text-align: center; border-bottom: none; border-top:none; background-color:#eeefef; padding-bottom:3px;}
    td:first-child{text-align:left; padding-left: 10px; padding-right:10px;}
    td:nth-child(2), td:nth-child(3){font-family: 'CodePro';}
    tr:last-child > td{padding-bottom:5px;}
    tr:nth-child(2) > td{padding-top:5px;}

    .bold{font-family: 'Helvetica';}
</style>
</head>
<body>
    <section class="container">
        <div class="slide">
            <ul class="controls">
                <li data-control="v">V</li>
                <li data-control="p">P</li>
                <li data-control="g">G</li>
                <li data-control="n">N</li>
                <li data-control="pi">PI</li>
                <li data-control="r">R</li>
            </ul>
            <article class="contents">
                <h1> 
                    <span><i>brilinta treatment</i></span><br>
                    <span>in guidelines<sup>1-4</sup></span> 
                </h1>

                <div data-slide="s0" >
                    <ul class='tablet small'>
                        <li><div>NZ CSANZ 2013<sup>1</sup><div></li>
                        <li><div>ESC 2011<sup>2</sup></div></li>
                        <li><div>ACC/AHA 2013<sup>3</sup></div></li>
                    </ul>
                </div>

                <div data-slide="s1" class="hide">
                    <table>
                        <tr>
                            <th>NSTE-ACS treated with medical management</th>
                            <th>class</th>
                            <th>level of evidence</th>
                        </tr>
                        <tr>
                            <td>Ticagrelor (180mg loading dose, 90mg bid) is recommended as the preferred P2Y<sub>12</sub> inhibitor.</td>
                            <td>I</td>
                            <td>B</td>
                        </tr>
                        <tr>
                            <td>Ticagrelor should be stopped 5 days prior to surgery.</td>
                            <td>I</td>
                            <td>C</td>
                        </tr>
                        <tr>
                            <td>Ticagrelor should be continued for 12 months after ACS including recommencement after CABG.</td>
                            <td>IIA</td>
                            <td>B</td>
                        </tr>
                    </table>
                </div>


                <div data-slide="s2" class="hide">
                    <table>
                        <tr>
                            <th>NSTE-ACS treated with medical management</th>
                            <th>CLASS</th>
                            <th>LEVEL OF EVIDENCE</th>
                        </tr>
                        <tr>
                            <td>A P2Y<sub>12</sub> inhibitor should be added to aspirin as soon as possible and maintained over 12 months unless there are contraindications such as excessive risk of bleeding.</td>
                            <td>I</td>
                            <td>A</td>
                        </tr>
                        <tr>
                            <td>Prolonged or permanent withdrawal of P2Y12 inhibitors within 12 months after
the index event is discouraged unless clinically indicated.</td>
                            <td>I</td>
                            <td>C</td>
                        </tr>
                         <tr>
                            <td>Ticagrelor (180mg loading dose, 90mg twice daily) is recommended for all patients at moderate-to-high risk of ischaemic events, regardless of initial treatment strategy and including those pre-treated with clopidogrel.</td>
                            <td>I</td>
                            <td>B</td>
                        </tr>
                         <tr>
                            <td>Clopidogrel is recommended for patients who cannot receive ticagrelor.</td>
                            <td>I</td>
                            <td>A</td>
                        </tr>
                    </table>
                </div>

                <div data-slide="s3" class="hide">
                    <table>
                        <tr>
                            <th>NSTE-ACS treated with medical management</th>
                            <th>class</th>
                            <th>level of evidence</th>
                        </tr>
                        <tr>
                            <td>In addition to aspirin, a P2Y<sub>12</sub> inhibitor (either clopidogrel or ticagrelor) should be continued for up to 12 months in all patients with NSTEACS without contraindications who are treated with an ischaemia-guided strategy.<br>
                            • ticagrelor: 90mg twice daily</td>
                            <td>I</td>
                            <td>B</td>
                            
                        </tr>
                        <tr>
                            <td>Ticagrelor in preference to clopidogrel for patients treated with an early invasive
or ischaemia-guided strategy</td>
                            <td>IIA</td>
                            <td>B</td>
                        </tr>
                    </table>
                </div>
                    
            </article>
            
           <span class="logo"></span>
           <span class="b-links plato">PLATO</span>
           <span class="b-links wallentin">WALLENTIN</span>
         
        </div><!-- end .slide -->
        <!--overlay -->
        <aside class="overlay hide"> 
            <!-- references -->
            <div class="ref">
                <h3>REFERENCE:</h3>
                <ol>
                    <li>Fox KAA et al. BMJ 2006; 33: 1091.</li>
                    <li>Fox KAA et al. Eur Heart J 2010; 31: 2755–2764.</li>
                    <li>Cutlip DE et al. Circulation 2004; 110: 1226–1230.</li>
                    <li>Nakatani D et al. Circ J 2013; 77: 439–446.</li>
                    <li>Farkouh ME, Mathew V. JACC Cardiovasc Imaging 2012; 5(3 Suppl): S73–S75.</li>
                    <li>Koek HL et al. Eur J Epidemiol 2007; 22: 883–888.</li>
                    <li>Gruppetta M et al. Clin Cardiol 2010; 33: 424–429.</li>
                    <li>Bhatt DL et al. JAMA 2010; 304: 1350–1357.</li>
                    <li>Husted S et al. Circ Cardiovasc Qual Outcomes 2012; 5: 680–688.</li>
                </ol>
            </div>
            <!-- Note -->
            <div class="notes hide">
                <h3>NOTES:</h3>
                European Society of Cardiology classes of recommendation and grading levels of evidence:<br>
                <br style='line-height:10px'>
                <span class='bold'>CLASSES OF RECOMMENDATION</span><br>
                Class I/Evidence and/or general agreement that a given treatment or procedure is beneficial, useful and effective<br>
                Class II. Conflicting evidence and/or divergence of opinion about the usefulness/efficacy of the given treatment or procedure<br>
                Class IIA. Weight of evidence/opinion is in favour of usefulness/efficacy<br>
                Class IIB. Usefulness/efficacy is less well established by evidence/opinion<br>
                Class III. Evidence and/or general agreement that a given treatment or procedure is not useful/effective, and in some cases
                could be harmful<br><br>
                <span class='bold'>LEVELS OF EVIDENCE</span><br>
                A. Data derived from multiple randomised clinical trials or meta-analysis<br>
                B. Data derived from a single randomised clinical trial or large non-randomised studies<br>
                C. Consensus of opinion of the experts and/or small studies, retrospective studies, registries<br>
            </div>
           
        </aside>
    </section>
<script type="text/javascript" src="js/jquery-1.11.0.min.js"></script>
<script type="text/javascript" src="js/touchy.js"></script>
<script type="text/javascript" src="js/script.js"></script>
<script type="text/javascript">
</script>
</body>
</html>
